Sutimlimab-jome
Customize your policy alerts
Sign up for healthspring Policy RX501.180 alerts
Get alerted when Policy RX501.180 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity coverage and authorization of sutimlimab-jome (Enjaymo) for adults with confirmed cold agglutinin disease and hemolysis. Non-approved FDA indications are considered experimental, investigational, and/or unproven.
The coverage criteria no longer require a positive polyspecific direct antiglobulin test (DAT).
Coverage Criteria
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.